Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 9/20 | 0.38 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27091101 | 0.68 | AKT1 (0.43) | ROCK2FAAHCDK2FLT3CCNA1 | |
| SCHEMBL1519772 | 0.63 | TDO2 (0.49) | ROCK2PIM1MAPTCDK2HIPK2 | |
| SCHEMBL3373407 | 0.60 | AKT2 (0.64) | ROCK2MAPT | |
| SCHEMBL31123095 | 0.60 | CDK2 (0.63) | ROCK2PIM1CDK2FLT3CCNA1 | |
| SCHEMBL19398637 | 0.59 | AKT1 (0.52) | ROCK2HIPK2 | |
| SCHEMBL30616953 | 0.57 | AKT2 (0.48) | PIM1MAPTCDK2FLT3CCNA1 | |
| SCHEMBL29077582 | 0.57 | AKT2 (0.48) | ROCK2PIM1CDK2FLT3CCNA1 | |
| SCHEMBL27091366 | 0.57 | AKT2 (0.48) | PIM1MAPTCDK2FLT3CCNA1 | |
| SCHEMBL20272947 | 0.57 | CLK1 (0.48) | MAPT | |
| SCHEMBL19914002 | 0.56 | PIM1 (0.40) | ROCK2PIM1HIPK2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | ROCK2 3267/4885LATS1 3522/4885LATS2 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.